Transcription of Therapeutic Class Overview Benign Prostatic …
{{id}} {{{paragraph}}}
Example: confidence
Therapeutic Class Overview Benign Prostatic …
Page 1 o f 6 Copyright 2014 Review Completed on 09/ 22/2014 Therapeutic Class Overview Benign Prostatic Hyperplasia Treatments Therapeutic Class Overview /Summary: The agents approved for the treatment of signs and symptoms of benignprostatic hyperplasia will be the focus of this review. The -adrenergic blockers including, alfuzosin,doxazosin, silodosin, tamsulosin, and terazosin, reduce smooth-muscle tone in the prostate andbladder neck decreasing lower urinary tract symptoms (LUTS) secondary to BPH. Alfuzosin, silodosinand tamsulosin are selective to the -adrenergic receptors located in the prostate and therefore areonly Food and Drug Administration (FDA) approved for BPH, whereas doxazosin and terazosinadditionally inhibit -adrenergic receptors found in the vascular smooth muscle and are additionallyindicated for The 5- r
• A systematic review of alfuzosin studies showed a greater improvement in the primary outcome (IPSS) over placebo (weighted mean difference, -1.8 points; 95% confidence interval [CI], -2.49 to -
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Overview, Benefit, Member Eligibility and Benefit Coverage, Near Infrared Spectroscopy, Technical Overview and Specification Summary, ISO 9001:2015 Overview, Introduction and Clauses, ISO 9001:2015 Overview, Introduction and Clauses 0, CAN (Controller Area Network), CAN (Controller Area Network) Transceivers